Want to see ALXO full AI Analyst Report?
ALXO Stock Chart & Stats
$2.00
$0.06(2.71%)
At close: 4:00 PM EDT
$2.00
$0.06(2.71%)
Day’s Range― - ―
52-Week Range$1.05 - $2.66
Previous CloseN/A
Volume153.64K
Average Volume (3M)985.39K
Market Cap
$240.60M
Enterprise Value$153.58
Total Cash (Recent Filing)$138.23M
Total Debt (Recent Filing)$9.71M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding138,277,000
10 Day Avg. Volume665,837
30 Day Avg. Volume985,389
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Loss And Burn TrendThe narrowing net loss and reduced cash burn indicate improving operating discipline relative to prior years, even though the company remains unprofitable. If sustained, this trend could extend available funding, support continued clinical development, and reduce the pace of future capital needs.
Relatively Modest Balance-sheet LeverageDebt remains modest relative to the reported equity base, giving ALX Oncology more flexibility than a highly leveraged development-stage company. This can help preserve capacity for research spending and financing actions while clinical programs advance, despite the need to manage ongoing losses.
Governance And Commercialization Leadership StrengthenedAdding experienced biopharmaceutical and legal leadership can strengthen governance and execution as ALX Oncology approaches important clinical and corporate milestones. The changes are intended to support evorpacept registration studies, ALX2004 progress, strategic partnerships, and eventual commercialization readiness.
Bears Say
No Reported Commercial RevenueWithout product revenue, the company has no established commercial engine to absorb research, development, and corporate costs. Progress therefore depends on clinical success, partnerships, or future commercialization, leaving financial performance structurally dependent on developments that have not yet produced recurring sales.
Persistent Operating And Free-cash-flow DeficitsSustained negative operating and free cash flow means ALX Oncology cannot currently fund its activities from internal cash generation. Continued pipeline investment will require available cash, collaboration proceeds, or additional financing, increasing exposure to funding needs while clinical programs remain in development.
Secured Financing Adds Covenant And Collateral ConstraintsThe loan facility provides capital access but introduces a more restrictive financial structure while cash burn remains substantial. Asset collateral, floating interest of at least 6% tied to prime, covenant limits, and potential default acceleration can constrain future options and raise execution risk.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $1.05 and its highest was $2.66 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $240.60M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Nov 05, 2026 which is in 47 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.013.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.13.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 138,277,000 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went up 9.896%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (100.00% Upside)
$4.00 (100.00% Upside)
Blogger Sentiment
Neutral
ALXO Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.00
▲(100.00% Upside)
Technical Analysis
Ownership Overview
9.79% Insiders
3.49% Mutual Funds
51.73% Other Institutional Investors
27.32% Public Companies and
Individual Investors